Autoimmune Conditions: Polymyalgia Rheumatica and Dermatomyositis

Area of Science:

• Rheumatology
• Immunology
• Internal Medicine

Background:

• Polymyalgia rheumatica (PMR) is a common systemic inflammatory disease in individuals over 70, presenting with neck, shoulder, and pelvic girdle pain and morning stiffness.
• Giant cell arteritis is a known comorbidity of PMR.
• Dermatomyositis is a rare inflammatory myopathy with characteristic skin lesions and proximal muscle weakness, potentially affecting other organs and associated with malignancy.

Purpose of the Study:

• To outline the key features and management of Polymyalgia Rheumatica.
• To describe the clinical presentation, systemic involvement, and treatment of Dermatomyositis.
• To highlight the role of glucocorticoids in managing these inflammatory myopathies.

Main Methods:

• Review of clinical characteristics and diagnostic criteria for PMR.
• Description of the typical presentation and progression of Dermatomyositis.
• Summary of standard treatment protocols, including glucocorticoid dosing and tapering strategies.

Main Results:

• PMR management typically involves prednisone 12.5-25 mg/day.
• Dermatomyositis treatment begins with prednisone 60 mg/day, with slow tapering to prevent relapse.
• Both conditions require careful monitoring for response and potential complications.

Conclusions:

• Glucocorticoids are the cornerstone of therapy for both Polymyalgia Rheumatica and Dermatomyositis.
• Early diagnosis and appropriate management are crucial for improving patient outcomes and preventing long-term sequelae.
• Understanding the distinct yet overlapping inflammatory pathways is key for effective treatment strategies.